Top section
Top section
◆ Predictions for Gulf issuance change shape again ◆ Investment grade firms to pick tricky path through autumn ◆ The Alphabet effect: hyperscalers hit Kangaroo market
Barclays is 21st in the CEEMEA bond league table so far in 2026
International investor participation in the region remains light
Data
More articles
More articles
More articles
-
China’s decision to clamp down on Ant Group has derailed an IPO of at least $34bn, despite execution being finished last week. The move appears to be little more than political muscle-flexing by Beijing. The real winners will be the country’s critics. -
The eventual result of Tuesday's US presidential election could have a monumental impact on the position of key emerging markets states like Russia and Turkey in the international arena.
-
Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has set the final terms for its Rp64.8bn ($866.5m) IPO in India.
-
Zhaoheng Hydropower (Hong Kong) has missed a payment on a 2017 dollar loan. It had extended the maturity on that deal earlier this year.
-
Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.
-
The Shanghai bourse stunned the market on Tuesday after halting Ant Group’s $34bn IPO, a deal which was set to be the largest listing in history. The extraordinary move, likely spurred by comments from Ant’s co-founder Jack Ma that criticised authorities for stifling innovation in China, is expected to delay the listing by at least six months. It will also force investors to revalue the company.
Sub-sections
-
Sponsored by CAF – Development Bank of Latin America and the Caribbean
CAF gearing up to transform regional development
-
Sponsored by Emirates NBD Capital
Emirates NBD Capital: An unrivalled conduit for Middle East liquidity
-
-
Sponsored by European Investment Bank
European Investment Bank: Supporting sustainable development in North Africa
